Revvity Inc (RVTY) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Revvity Inc  (NYSE: RVTY)

Select the Financial Report: Select the Period:


Description of Revvity Inc's Business Segments


Revvity Inc. is a company that specializes in providing advanced technology solutions aimed at scientific and research-based industries. They focus on streamlining the process of data analysis, visualization, and collaboration to bolster scientific breakthroughs and discoveries. Here’s an extensive overview of their segments, products, and services:

Segments

1. Life Sciences: Revvity caters to various sectors within the life sciences domain, including pharmaceuticals, biotechnology, and academic research institutions. The products and services are tailored to facilitate drug discovery, clinical research, and data management.

2. Chemistry and Materials Science: This segment focuses on chemical applications, offering tools for materials characterization, molecular modeling, and data analytics. The solutions aim to improve research efficiency and enhance innovation in material development.

3. Health Solutions: Revvity provides specialized services and software for healthcare professionals, aiding in processes like patient data management, diagnostics, and personalized medicine.

4. Data Management and Analytics: Revvity’s offerings extend to data analytics solutions that help organizations manage vast sets of research data, providing insights and facilitating decision-making.

Products

1. Scientific Software Platforms: Revvity offers a variety of software solutions designed for specific scientific applications. These platforms allow researchers to analyze, manage, and visualize their data with ease and efficiency.

- Molecular Visualization Tools: Software for visualizing complex molecular structures, aiding researchers in understanding molecular interactions and properties.
- Data Analytics Software: Tools that provide comprehensive analytics and reporting functionalities to enhance the interpretation of scientific data.

2. Collaboration Platforms: These products facilitate seamless communication and collaboration among research teams. They often feature options for document sharing, project management, and version control, tailored for scientific environments.

3. Cloud Solutions: Revvity’s cloud-based offerings ensure that clients can access and analyze data remotely, providing flexibility and promoting collaboration across geographies. This includes data storage, sharing capabilities, and analytics in a secure environment.

4. Laboratory Information Management Systems (LIMS): These systems help organizations manage samples, associated data, and laboratory workflows efficiently. By automating processes and ensuring compliance, LIMS assists researchers in focusing more on experimentation rather than administrative tasks.

Services

1. Consulting Services: Revvity provides consulting to help organizations optimize their research processes and workflows. These services involve analyzing current practices, offering tailored solutions, and providing strategic advice on technology adoption.

2. Training and Support: With a focus on enabling users to maximize the advantages of their tools, Revvity offers training programs that guide clients in making the most of their products. This may include workshops, webinars, or one-on-one training sessions.

3. Custom Software Development: Recognizing the unique requirements of different clients, Revvity offers bespoke software development services. This allows organizations to obtain fully tailored solutions that fit seamlessly into their existing workflows.

4. Technical Support Services: Revvity provides ongoing technical support to assist clients in troubleshooting, ensuring that they can operate their systems without interruption. This service is crucial for maintaining productivity in research settings.

5. Integration Services: Revvity aids clients in integrating their existing systems with new software solutions, ensuring a smooth transition and continuity of operations. This is particularly important in environments with established processes and data ecosystems.

Conclusion

Overall, Revvity Inc. positions itself as a key player in the landscape of scientific research, offering a comprehensive suite of products and services designed to optimize workflows, enhance collaboration, and facilitate innovation across various industries. Their dedication to advancing technologies in life sciences, chemistry, and healthcare makes them a valuable partner for organizations striving for scientific excellence.


Composition of Revvity Inc Revenues by Segments

 
Product    162.38 % of total Revenue
Service    35.07 % of total Revenue
Life Sciences    98.75 % of total Revenue
Diagnostics    98.71 % of total Revenue
Americas    87.92 % of total Revenue
Europe    61.96 % of total Revenue
Asia    47.57 % of total Revenue
Reportable Segment Revenue    197.46 % of total Revenue

Q2 three months ended (Jul 05 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Product 1,184.87 162.38 %
Service 255.94 35.07 %
Life Sciences 720.54 98.75 %
Diagnostics 720.26 98.71 %
Americas 641.58 87.92 %
Europe 452.09 61.96 %
Asia 347.14 47.57 %
Reportable Segment Revenue 1,440.81 197.46 %
Total 729.69 100 %




Q2 three months ended (Jul 05 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Product 94.02 % 103.78 %
Service 133.56 % 97.39 %
Life Sciences 96.92 % 99.13 %
Diagnostics 103.24 % 106.22 %
Americas 98.27 % 103.04 %
Europe 122.01 % 102.69 %
Asia 79.8 % 101.73 %
Reportable Segment Revenue - -
Total 1.31 % 2.61 %




Q2 three months ended (Jul 05 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total 51.82 7.1 %




Q2 three months ended (Jul 05 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total -3.94 % 27.27 %




Annual Report on Revvity Inc Divisions, Sales by Country

 
Life Sciences   Life Sciences Segment contribution to total sales 50.11 % of total Revenue
Diagnostics   Diagnostics Segment contribution to total sales 49.89 % of total Revenue
Americas   Americas Segment contribution to total sales 43.98 % of total Revenue
Europe   Europe Segment contribution to total sales 28.89 % of total Revenue
Asia   Asia Segment contribution to total sales 27.14 % of total Revenue
Life Sciences Solutions   Life Sciences Solutions Segment contribution to total sales 41.83 % of total Revenue
Software   Software Segment contribution to total sales 8.28 % of total Revenue
Reproductive health   Reproductive health Segment contribution to total sales 19.43 % of total Revenue
Immunodiagnostics   Immunodiagnostics Segment contribution to total sales 30.46 % of total Revenue
Diagnostics Americas   Diagnostics Americas Segment contribution to total sales 17.69 % of total Revenue
Diagnostics Europe   Diagnostics Europe Segment contribution to total sales 16.86 % of total Revenue
Diagnostics Asia   Diagnostics Asia Segment contribution to total sales 15.35 % of total Revenue
Life Sciences Americas   Life Sciences Americas Segment contribution to total sales 26.29 % of total Revenue
Life Sciences Europe   Life Sciences Europe Segment contribution to total sales 12.03 % of total Revenue
Life Sciences Asia   Life Sciences Asia Segment contribution to total sales 11.79 % of total Revenue
Life Sciences Solutions Life Sciences   Life Sciences Solutions Life Sciences Segment contribution to total sales 41.83 % of total Revenue
Software Life Sciences   Software Life Sciences Segment contribution to total sales 8.28 % of total Revenue
Reproductive health Diagnostics   Reproductive health Diagnostics Segment contribution to total sales 19.43 % of total Revenue
Immunodiagnostics Diagnostics   Immunodiagnostics Diagnostics Segment contribution to total sales 30.46 % of total Revenue
Reportable Revenue   Reportable Revenue Segment contribution to total sales 100 % of total Revenue
Diagnostics Reportable Revenue   Diagnostics Reportable Revenue Segment contribution to total sales 49.89 % of total Revenue
Diagnostics Income   Diagnostics Income Segment contribution to total sales 22.19 % of total Revenue
Life Sciences Reportable Revenue   Life Sciences Reportable Revenue Segment contribution to total sales 50.11 % of total Revenue
Life Sciences Income   Life Sciences Income Segment contribution to total sales 18.08 % of total Revenue
UNITED STATES   UNITED STATES Segment contribution to total sales 39.43 % of total Revenue
CHINA   CHINA Segment contribution to total sales 14.88 % of total Revenue
UNITED KINGDOM   UNITED KINGDOM Segment contribution to total sales 4.44 % of total Revenue
GERMANY   GERMANY Segment contribution to total sales 6.22 % of total Revenue
Other International   Other International Segment contribution to total sales 35.02 % of total Revenue
Total international   Total international Segment contribution to total sales 60.57 % of total Revenue


Twelve months ended 2025
RVTY s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Life Sciences 1,431.10 50.11 %
Diagnostics 1,424.95 49.89 %
Americas 1,255.96 43.98 %
Europe 824.98 28.89 %
Asia 775.11 27.14 %
Total 2,856.05 100 %
Life Sciences Solutions 1,194.73 41.83 %
Software 236.38 8.28 %
Reproductive health 555.04 19.43 %
Immunodiagnostics 869.91 30.46 %
Diagnostics Americas 505.10 17.69 %
Diagnostics Europe 481.47 16.86 %
Diagnostics Asia 438.37 15.35 %
Life Sciences Americas 750.86 26.29 %
Life Sciences Europe 343.51 12.03 %
Life Sciences Asia 336.74 11.79 %
Life Sciences Solutions Life Sciences 1,194.73 41.83 %
Software Life Sciences 236.38 8.28 %
Reproductive health Diagnostics 555.04 19.43 %
Immunodiagnostics Diagnostics 869.91 30.46 %
Reportable Revenue 2,856.05 100 %
Diagnostics Reportable Revenue 1,424.95 49.89 %
Diagnostics Income 633.77 22.19 %
Life Sciences Reportable Revenue 1,431.10 50.11 %
Life Sciences Income 516.30 18.08 %
UNITED STATES 1,126.27 39.43 %
CHINA 425.06 14.88 %
UNITED KINGDOM 126.85 4.44 %
GERMANY 177.66 6.22 %
Other International 1,000.20 35.02 %
Total international 1,729.78 60.57 %


Twelve months ended 2025
RVTY s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total 241.20 8.45 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Life Sciences 2.32 % -
Diagnostics 5.05 % -
Americas 2.69 % -
Europe 11.09 % -
Asia -1.8 % -
Total 3.67 % -10.79 %
Life Sciences Solutions -0.26 % -
Software 17.72 % -
Reproductive health 5.16 % -
Immunodiagnostics 4.98 % -
Diagnostics Americas 5.7 % -
Diagnostics Europe 12.64 % -
Diagnostics Asia -2.82 % -
Life Sciences Americas 0.76 % -
Life Sciences Europe 8.99 % -
Life Sciences Asia -0.44 % -
Life Sciences Solutions Life Sciences -0.26 % -
Software Life Sciences 17.72 % -
Reproductive health Diagnostics 5.16 % -
Immunodiagnostics Diagnostics 4.98 % -
Reportable Revenue 3.67 % -
Diagnostics Reportable Revenue 5.05 % -
Diagnostics Income 10 % -
Life Sciences Reportable Revenue 2.32 % -
Life Sciences Income 5.76 % -
UNITED STATES 2.59 % -
CHINA -5.54 % -
UNITED KINGDOM 12.37 % -
GERMANY 9.28 % -
Other International 7.35 % -
Total international 4.38 % -
Life Sciences reagents - -
Life Sciences reagents Life Sciences - -
Life Sciences instruments - -
Life Sciences instruments Life Sciences - -
Life Sciences software - -
Life Sciences software Life Sciences - -
Applied genomics - -
Applied genomics Diagnostics - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.